Rate My Professor Romald Gartenhaus

An accomplished physician-scientist, Gartenhaus is renowned for his contributions to the understanding of lymphoma biology, with a focus on post-transcriptional and translational mechanisms of gene regulation and oncogenic signaling pathways amenable to targeted therapeutic intervention. His laboratory pioneered the identification of the MCT-1 oncogene in T-cell lymphoma. He has authored over 80 original research articles in high-impact journals, including notable publications such as "The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future" (Leukemia Research, 2004), "Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism" (British Journal of Cancer, 2007), "Expression of alternatively spliced human T-lymphotropic virus type I pX mRNA in infected cell lines and in primary uncultured cells from patients with adult T-cell leukemia/lymphoma" (Proceedings of the National Academy of Sciences, 1992), and more recent works on eIF4A1 inhibitors and USP11 in lymphoma. Holding two U.S. patents, his research has been continuously funded for over 15 years by NIH grants, VA Merit Review Awards, and national foundations. Gartenhaus has served on NIH and VA study sections, editorial boards including as associate editor for PLOS Genetics, and as a mentor directing postdoctoral programs and training numerous researchers. In 2017, he was awarded a sabbatical as a visiting scholar at the Institute for Advanced Studies at Hebrew University in Jerusalem to study adaptive immunity and cancer.